Stockreport

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® [Yahoo! Finance]

Alvotech  (ALVO) 
PDF Sales of Entyvio (vedolizumab) were about $5.4 billion globally in the last 12 months up to June 30, 2024 Entyvio is indicated for the treatment of Ulcerative Colitis [Read more]